Cecilia Jimeno [and seven others] Jimeno, Cecilia Anonuevo-Cruz, Ma. Cecille Bea Uy, Angelique Bacena, Adrian Oscar Francisco, Mark David Tiglao-Gica, Angelique Love Bruno, Racquel Corpuz, Diane Grace text monographic eng

print

Diabetes mellitus (DM) is a known risk factor for morbidity and mortality among patients with COVID-19 based on recent studies. While there are many local and international guidelines on inpatient management of diabetes, the complicated pathology of the virus, the use of glucose-elevating drugs such as glucocorticoids, antivirals and even inotropes, and various other unique problems has made the management of in-hospital hyperglycemia among patients with COVID-19 much more difficult than in other infections. The objective of this guidance is to collate and integrate the best available evidence that has been published regarding in-patient management of diabetes among patients with COVID-19. A comprehensive review of literature was done and recommendations have been made through a consensus of expert endocrinologists from the University of the Philippines-Philippine General Hospital (UP-PGH) Division of Endocrinology, Diabetes and Metabolism. These recommendations are evolving as we continue to understand the pathology of the disease and how persons with diabetes are affected by this virus. In: JAFES 2020; vol. 35 (1) pages: 14-25 COVID-19 Diabetes Mellitus In-patient Management https://www.asean-endocrinejournal.org/index.php/JAFES/article/view/821 https://www.asean-endocrinejournal.org/index.php/JAFES/article/view/821 210109 20210109104153.0 D0001C000087